Market Closed -
Australian S.E.
11:15:38 03/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.38
AUD
|
-3.80%
|
|
-6.17%
|
-20.00%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
79.39
|
63.1
|
31.51
|
85.5
|
43.65
|
16.75
|
Enterprise Value (EV)
1 |
69.55
|
60.74
|
31.54
|
86.08
|
46.12
|
26.27
|
P/E ratio
|
-9.01
x
|
-27.2
x
|
-1.43
x
|
-4.44
x
|
-2.02
x
|
-0.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
267
x
|
96.1
x
|
15.2
x
|
28.9
x
|
9.22
x
|
4.95
x
|
EV / Revenue
|
234
x
|
92.6
x
|
15.2
x
|
29.1
x
|
9.75
x
|
7.75
x
|
EV / EBITDA
|
-10.3
x
|
-7.19
x
|
-2.88
x
|
-7.65
x
|
-2.99
x
|
-1.79
x
|
EV / FCF
|
-97.2
x
|
-6.2
x
|
-5.24
x
|
-6.95
x
|
-5.24
x
|
-4.73
x
|
FCF Yield
|
-1.03%
|
-16.1%
|
-19.1%
|
-14.4%
|
-19.1%
|
-21.1%
|
Price to Book
|
5.7
x
|
5.76
x
|
10.1
x
|
6.2
x
|
7.48
x
|
-2.26
x
|
Nbr of stocks (in thousands)
|
1,203
|
1,213
|
1,576
|
2,311
|
2,728
|
3,351
|
Reference price
2 |
66.00
|
52.00
|
20.00
|
37.00
|
16.00
|
5.000
|
Announcement Date
|
02/09/18
|
28/08/19
|
30/09/20
|
30/09/21
|
02/10/22
|
29/09/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.2968
|
0.6562
|
2.079
|
2.963
|
4.732
|
3.388
|
EBITDA
1 |
-6.725
|
-8.452
|
-10.96
|
-11.25
|
-15.4
|
-14.69
|
EBIT
1 |
-7.053
|
-8.712
|
-11.29
|
-11.59
|
-15.5
|
-15.23
|
Operating Margin
|
-2,376.25%
|
-1,327.51%
|
-542.8%
|
-391.22%
|
-327.54%
|
-449.72%
|
Earnings before Tax (EBT)
1 |
-8.99
|
-1.876
|
-18.77
|
-15.44
|
-20.77
|
-21.13
|
Net income
1 |
-8.246
|
-2.309
|
-19.36
|
-15.87
|
-20.35
|
-20.82
|
Net margin
|
-2,778.31%
|
-351.91%
|
-931.29%
|
-535.62%
|
-430%
|
-614.71%
|
EPS
2 |
-7.327
|
-1.910
|
-14.03
|
-8.343
|
-7.929
|
-7.100
|
Free Cash Flow
1 |
-0.7154
|
-9.801
|
-6.022
|
-12.38
|
-8.806
|
-5.55
|
FCF margin
|
-241.03%
|
-1,493.47%
|
-289.63%
|
-417.95%
|
-186.09%
|
-163.85%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/09/18
|
28/08/19
|
30/09/20
|
30/09/21
|
02/10/22
|
29/09/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
0.03
|
0.58
|
2.47
|
9.51
|
Net Cash position
1 |
9.84
|
2.35
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.002358
x
|
-0.0519
x
|
-0.1601
x
|
-0.6475
x
|
Free Cash Flow
1 |
-0.72
|
-9.8
|
-6.02
|
-12.4
|
-8.81
|
-5.55
|
ROE (net income / shareholders' equity)
|
-63.1%
|
-16.2%
|
-270%
|
-182%
|
-219%
|
1,482%
|
ROA (Net income/ Total Assets)
|
-21.6%
|
-33%
|
-67.4%
|
-45%
|
-45.3%
|
-66.7%
|
Assets
1 |
38.18
|
6.996
|
28.72
|
35.23
|
44.94
|
31.21
|
Book Value Per Share
2 |
11.60
|
9.030
|
1.970
|
5.960
|
2.140
|
-2.210
|
Cash Flow per Share
2 |
8.200
|
1.940
|
1.190
|
2.340
|
0.6900
|
0.0700
|
Capex
1 |
0.46
|
0.38
|
0.96
|
3.33
|
2.69
|
0.19
|
Capex / Sales
|
154.79%
|
57.46%
|
46.27%
|
112.29%
|
56.91%
|
5.6%
|
Announcement Date
|
02/09/18
|
28/08/19
|
30/09/20
|
30/09/21
|
02/10/22
|
29/09/23
|
|
1st Jan change
|
Capi.
|
---|
| +39.33% | 6.11B | | -18.38% | 4.35B | | -9.17% | 3.19B | | +3.98% | 3.15B | | -3.41% | 2.51B | | +48.74% | 1.98B | | -4.82% | 1.74B | | -1.24% | 1.63B | | -8.96% | 1.6B |
Alternative Medicine
|